These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8511091)

  • 1. [Pre-exposure rabies immunization in occupational exposed milieu. A 5-year prospective and comparative study of immunogenicity].
    Strady A; Lienard M; Ajjan N
    Presse Med; 1993 Apr; 22(12):572-6. PubMed ID: 8511091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].
    Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA
    Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers".
    Ranney M; Partridge R; Jay GD; Rozzoli DE; Pandey P
    J Travel Med; 2006; 13(6):329-33. PubMed ID: 17107424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).
    Lang J; Cetre JC; Picot N; Lanta M; Briantais P; Vital S; Le Mener V; Lutsch C; Rotivel Y
    Biologicals; 1998 Dec; 26(4):299-308. PubMed ID: 10403033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.
    Strady A; Lang J; Lienard M; Blondeau C; Jaussaud R; Plotkin SA
    J Infect Dis; 1998 May; 177(5):1290-5. PubMed ID: 9593014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Pichon S; Moureau A; Petit C; Chu L; Essink B; Muse D; Saleh J; Guinet-Morlot F; Minutello AM
    Vaccine; 2022 Aug; 40(33):4780-4787. PubMed ID: 35778281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Janewongwirot P; Jantarabenjakul W; Anugulruengkitt S; Anunsittichai O; Saengseesom W; Buranapraditkun S; Sophonphan J; Wacharachaisurapol N; Jitrungruengnij N; Pancharoen C; Puthanakit T
    Vaccine; 2019 Aug; 37(36):5307-5313. PubMed ID: 31358408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and booster efficacy of pre-exposure rabies vaccination.
    Strady C; Andreoletti L; Baumard S; Servettaz A; Jaussaud R; Strady A
    Trans R Soc Trop Med Hyg; 2009 Nov; 103(11):1159-64. PubMed ID: 19359026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore.
    Lim PL; Barkham TM
    Int J Infect Dis; 2010 Jun; 14(6):e511-3. PubMed ID: 20018545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pre-exposure rabies vaccination using a new duck embryo vaccine].
    Bachmann G; Steffen R; Glück R; Wegmann A; Schär M
    Schweiz Med Wochenschr; 1985 Jun; 115(25):863-5. PubMed ID: 4023675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine.
    Gherardin AW; Scrimgeour DJ; Lau SC; Phillips MA; Kass RB
    J Travel Med; 2001; 8(3):122-6. PubMed ID: 11468113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies.
    Lang J; Gravenstein S; Briggs D; Miller B; Froeschle J; Dukes C; Le Mener V; Lutsch C
    Biologicals; 1998 Mar; 26(1):7-15. PubMed ID: 9637744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination.
    Bernard KW; Mallonee J; Wright JC; Reid FL; Makintubee S; Parker RA; Dwyer DM; Winkler WG
    JAMA; 1987 Feb; 257(8):1059-63. PubMed ID: 3806894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.
    Manning SE; Rupprecht CE; Fishbein D; Hanlon CA; Lumlertdacha B; Guerra M; Meltzer MI; Dhankhar P; Vaidya SA; Jenkins SR; Sun B; Hull HF;
    MMWR Recomm Rep; 2008 May; 57(RR-3):1-28. PubMed ID: 18496505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
    Quiambao BP; Lim JG; Bosch Castells V; Augard C; Petit C; Bravo C; Delore V; Houillon G
    Vaccine; 2022 Aug; 40(36):5347-5355. PubMed ID: 35933278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine.
    Sabchareon A; Chantavanich P; Pasuralertsakul S; Pojjaroen-Anant C; Prarinyanupharb V; Attanath P; Singhasivanon V; Buppodom W; Lang J
    Pediatr Infect Dis J; 1998 Nov; 17(11):1001-7. PubMed ID: 9849982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.